Menu

Latest news & events

Team Science grant Uyen Nguyen and Roel Meiburg

Team Science grant Uyen Nguyen and Roel Meiburg

18 December 2024

Dr Uyen Nguyen (Dept of Cardiology) and Dr Roel Meiburg (Biomedical Engineer, TU Eindhoven) have been awarded a Dekker Team Science grant by the Dutch Heart Foundation.

Read more
ZonMw grant on appropriate palliative care

ZonMw grant on appropriate palliative care

10 December 2024

Prof. Marc Hemmelder (Dept of Internal Medicine) and his team received a ZonMw grant to promote early palliative care for dialysis patients who are non-waitlisted for transplantation.
 

Read more
More newsMore events
Carim Maastricht
Carim Maastricht

Martijn Brouwers

Professor

Dr Martijn Brouwers obtained his MD degree (with honours) in 2002, after which he started his PhD project that focused on hepatic steatosis in familial combined hyperlipidemia. In 2006, he worked as a trainee at the Department of Internal Medicine and Endocrinology. Since 2012, he has been a staff member (internist-endocrinologist) at Maastricht UMC+ and in 2019 he was appointed as the head of the division of Endocrinology and Metabolic Disease.

His research focusses on the cardiometabolic consequences of nonalcoholic fatty liver disease (NAFLD). NAFLD consists of a histological spectrum comprising simple steatosis, steatohepatitis (NASH), fibrosis and cirrhosis. Evidence is accumulating that NAFLD is not only a liver disease per se, it is also a risk factor for type 2 diabetes, chronic kidney disease and cardiovascular disease. This research line aims to elucidate the exact mechanistic link between NAFLD and these systemic diseases. For this, a diverse set of studies is used, ranging from (genetic) epidemiology, to ‘human knockout’ models, to randomised controlled trials and experimental animal work. This research is in part funded by the Dutch Heart Foundation, the Dutch Diabetes Foundation and the European Foundation for the Study of Diabetes.

Brouwers pasfoto

Department ofInternal Medicine
P. Debeyelaan 25, 6229 HX Maastricht 
PO Box 5800, 6202 AZ Maastricht
T: +31(0)43 388 70 19

  • 2010
    • Brouwers, M. C., de Graaf, J., van Greevenbroek, M. M. J., Schaper, N. C., Stehouwer, C. D. A., & Stalenhoef, A. F. (2010). Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.Current Opinion in Lipidology, 21(6), 530-538. https://doi.org/10.1097/MOL.0b013e32833ea9ec
  • 2009
    • Brouwers, M. C., Reesink, K. D., van Greevenbroek, M. M., Meinders, J. M., van der Kallen, C. J., Schaper, N., Hoeks, A. P., & Stehouwer, C. D. (2009). Increased arterial stiffness in familial combined hyperlipidemia. Journal of Hypertension, 27(5), 1009-16. https://doi.org/10.1097/HJH.0b013e32832991fa
  • 2008
    • Brouwers, M. C., Dekker, J. M., van Greevenbroek, M. M., van der Kallen, C. J., Heine, R. J., de Bruin, T. W., & Stehouwer, C. D. (2008). Plasma triglycerides and LDL cholesterol are related in a parabolic fashion in the general population and patients with Type 2 diabetes mellitus: long-term follow-up results from the Hoorn study. Diabetic Medicine, 25(9), 1121-4. https://doi.org/10.1111/j.1464-5491.2008.02524.x
  • 2007
    • Wang, P., van Greevenbroek, M. M., Bouwman, F. G., Brouwers, M. C., van der Kallen, C. J. H., Smit, E., Keijer, J., & Mariman, E. C. (2007). The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Archiv-European Journal of Physiology, 454(6), 971-976. https://doi.org/10.1007/s00424-007-0262-y
Overview